EZH2 and plasma cell myeloma: Studies have indicated that the dual inhibition of DNMTs and EZH2 can eliminate the inherent and acquire drug resistance of myeloma cells to IMiDs in a brain-independent way29, which will perhaps play a more contributing role in the treatment of malignant mesothelioma, which is worthy of further study and exploration30.